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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Estonian lan-
guage. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (conver-
gent and discriminant validity). A total of 110 JIA patients (71.8% oligoarticular, 18.2% RF-negative polyarthritis, 10% other 
categories) and 98 healthy children were enrolled in one paediatric rheumatology centre. Notably, none of the enrolled JIA 
patients is affected with systemic JIA. The JAMAR components discriminated healthy subjects from JIA patients, except 
for the Paediatric Rheumatology Quality of Life (HRQoL) Psychosocial Health (PsH) subscales and for the satisfaction 
with current health status. All JAMAR components revealed good psychometric performances. In conclusion, the Estonian 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Estonian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
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(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Estonian language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from October 2011 
to July 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of 10 JIA par-
ents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
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equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with 1st and 3rd quartiles and categorical data as absolute 
frequencies and percentages.
The complete Estonian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Estonian JAMAR was fully cross-culturally adapted 
with two forward and two backward translations. The con-
cordance rate between the original standard English version 
of the JAMAR and the two back-translations was 94.5% 
(115/123 lines) for the parent version and 97.5% (117/120 
lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 90–100%). Of the 120 lines in the 
patient version of the JAMAR, 113 (94%) lines were under-
stood by at least 80% of the children (median = 100%; range 
10–100%). Lines 3, 10, 29, 48, 94, 116, 119 of the child 
version of the JAMAR were modified considering patients’ 
suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 110 JIA patients and 100 healthy children (total of 
210 subjects) were enrolled at the paediatric rheumatology 
centre of Tartu University Hospital, Children’s Clinic. Two 
healthy children did not give the consent to use their data.
In the 110 JIA subjects, the JIA categories were 71.8% 
with oligoarthritis, 18.2% with RF-negative polyarthritis, 
1.8% with RF-positive polyarthritis, 1.8% with psoriatic 
arthritis, 1.8% with enthesitis-related arthritis and 4.6% with 
undifferentiated arthritis. Notably, none of the enrolled JIA 
patients is affected with systemic JIA (Table 1).
All the 208 subjects had the parent version of the JAMAR 
completed by a parent (110 from parents of JIA patients 
and 98 from parents of healthy children). The JAMAR was 
completed by 192/208 (92.3%) mothers and 16/208 (7.7%) 
fathers. The child version of the JAMAR was completed by 
205/208 (98.5%) children age 7.5 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores (median (1st–3rd quartile)) obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in psychosocial quality of life items and sat-
isfaction with current health status.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. “Results” 
refers mainly to the parent’s version findings, unless other-
wise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items since 
data were collected through a web-based system that 
did not allow to skip answers and input null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the differ-
ent HRQoL items except for items 1 and 8, whereas a 
reduced number of response choices were used for all the 
PF items except for item 4. The mean and SD of the items 
within a scale were roughly equivalent for the PF and for 
the HRQoL items, except for HRQoL items 1 and 8 (data 
not shown). The median number of items marked as not 
applicable was 0% (0–0%) for the PF and 1% (1–1%) for 
the HRQoL.
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Floor and ceiling effect
The median floor effect was 86.4% (69.1–91.8%) for the 
PF items, 48.2% (23.6–53.6%) for the HRQoL PhH items, 
and 51.8% (46.4–52.7%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0.0%) for the PF items, 
1.8% (0.9–5.5%) for the HRQoL PhH items, and 1.8% 
(1.8–3.6%) for the HRQoL PsH items. The median floor 
effect was 21.8% for the pain VAS, 21.8% for the disease 
activity VAS and 22.7% for the well-being VAS. The 
median ceiling effect was 0.9% for the pain VAS, 0.9% for 
the disease activity VAS and 1.8% for the well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 110/208 Child N = 110/205
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 86.4% 88.2%
 HRQoL PhH 48.2% 55.5%
 HRQoL PsH 51.8% 59.1%
 Pain VAS 21.8% 24.5%
 Disease activity VAS 21.8% 23.6%
 Well-being VAS 22.7% 33.6%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 1.8% 0.9%
 HRQoL PsH 1.8% 0.0%
 Pain VAS 0.9% 0.9%
 Disease activity VAS 0.9% 0.0%
 Well-being VAS 1.8% 0.9%
Items with equivalent item–scale correlation 80% for PF, 100% for HRQoL 87% for PF, 80% for HRQoL
Items with item–scale correlation ≥ 0.4 80% for PF, 100% for HRQoL 87% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.79 0.77
 PF-HW 0.64 0.77
 PF-US 0.76 0.72
 HRQoL-PhH 0.84 0.78
 HRQoL-PsH 0.82 0.77
Items with item–scale correlation lower than the Cronbach’s alpha 93% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.99
 HRQoL-PhH 1.0 1.0
 HRQoL-PsH 1.0 1.0
Spearman correlation with JIA core set variables, median
 PF 0.5 0.4
 HRQoL PhH 0.4 0.4
 HRQoL PsH 0.2 0.3
 Pain VAS 0.1 0.1
 Disease activity VAS 0.2 0.1
 Well-being VAS 0.1 0.1
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Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the 
PF items, with the exception of PF items 9, 11 and 15, and 
for 100% of the HRQoL items.
Items’ internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 80% of 
items of the PF (except for PF items 9, 10 and 15) and 
100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.79 for PF-LL, 0.64 for PF-HW, 
and 0.76 for PF-US. Cronbach’s alpha was 0.84 for 
HRQoL-PhH and 0.82 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha 
except for the PF item 8.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 1 day (0–5 days). The intraclass correla-
tion coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 1.0). The ICC for the 
HRQoL PhH and for the HRQoL PsH showed an almost 
perfect reproducibility (ICC = 1 for both).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.1 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). The correlation of the PF total score with the 
ESR and with the number of active joints was not signifi-
cant (p = 0.83 and p = 0.28, respectively). For the HRQoL, 
the median correlation of the PhH with the JIA core set of 
outcome variables ranged from 0.1 to 0.6 (median = 0.4), 
whereas for the PsH ranged from 0.1 to 0.4 (median = 0.2). 
The PhH showed the best correlation with the parent’s 
assessment of pain (r = 0.7, p < 0.001) and the PsH with the 
parent global assessment of well-being (r = 0.5, p < 0.001). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.1 (0.1–0.3), 0.2 
(0.2–0.3), 0.1 (0.03–0.2), respectively.
Discussion
In this study, the Estonian version of the JAMAR was fully 
cross-culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the Esto-
nian parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. Notably, there was 
no significant difference between the healthy subjects and 
their affected peers in the psychosocial quality of life and in 
the satisfaction with disease outcome variables. This finding 
indicates that children with JIA adapt well to the conse-
quences of JIA.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: three PF items (open a 
door by lowering the handle, open and close a tap or open a 
previously open jar and bite a sandwich or an apple) showed 
a lower items internal consistency and the Cronbach’s alpha 
for PF-HW was questionable. However, the overall internal 
consistency for the remaining domains was good.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from very weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Estonian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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